COMPARATIVE STUDY ON EFFICACY AND SAFETY OF VILDAGLIPTIN-METFORMIN VS GLIMEPIRIDE-METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Registration ID: IJNRD_206919

Published ID: IJNRD2311002

DOI: Click Here to Get

Bismi B , Jyothy A , Krishna M S , Sabna Sobhanan

DM-Diabetes Mellitus, PPG-Post prandial glucose, FPG-Fasting blood plasma glucose, HbA1c-Hemoglobin A1C

The aim of the study was to compare the efficacy and safety of vildagliptin-metformin Vs glimepiride metformin in patients with type 2 DM. A comparative study was conducted over a period of three months in a tertiary care hospital. In this study the primary goal was a reduction in HbA1c from baseline and secondary goal included fasting plasma glucose (FPG) or postprandial glucose (PPG) reduction from baseline, as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category. Among the study population N=102, comparable HbA1c reduction was observed with a mean±standard deviation change from baseline in the vildagliptin group and -1.00±1.32% in the glimepiride group. A similar reduction in PPG (vildagliptin group 3.53±4.11 mmol/L vs. the glimepiride group 3.72±4.17 mmol/L) was demonstrated, and the decrements in FPG (vildagliptin group 1.54±2.41 mmol/L vs. glimepiride group 2.16±2.51 mmol/L) were not different between groups. The proportion of patients who achieved an HbA1c less than 7% in the vildagliptin group and 56.0% in the glimepiride group. An average body weight gain in the glimepiride group was observed in contrast with the weight gain noted in the vildagliptin group. A 10-fold lower incidence of hypoglycemia was demonstrated in the vildagliptin group, in addition to an absence of severe hypoglycemia. The study concluded that vildagliptin-metformin treatment provided blood glucose control efficacy comparable to that of glimepiride-metformin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain.

Published Paper   E-Certificate

Bismi B , Jyothy A, Krishna M S, & Sabna Sobhanan (November-2023). COMPARATIVE STUDY ON EFFICACY AND SAFETY OF VILDAGLIPTIN-METFORMIN VS GLIMEPIRIDE-METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(11), a26-a33. https://ijnrd.org/papers/IJNRD2311002.pdf

Volume 8 Issue 11, November-2023

Pages : a26-a33

Paper Reg. ID: IJNRD_206919

Published Paper Id: IJNRD2311002

Downloads: 000121977

Research Area: Science

Country: Alappuzha , Kerala, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2311002.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2311002

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

By Our website

Click Here to Submit Paper Online

By Mail

Send your paper to editor@ijnrd.org

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details